Topics covered:
1) 0:00 Announcements
2) 0:35 Market Commentary and Index Review (Nasdaq Composite, S&P 500, and Russell 2000
3) 15:20 FOCUS LIST: NVDA, TSM, PLTR, TSLA, LLY, RKLB, ASTS, XBI (ETF)
4) 18:35 Stock Review – Aerospace/Defense: PL, ATRO, WWD, HXL, GE, HWM, RTX, SATS, RDW, LUNR
5) 20:35 Stock Review – Semiconductors and Data Storage: SMH (ETF), AVGO, TSEM, LRCX, KLAC, MU, AEIS, MTSI, TER, STX, WDC, SNDK
6) 22:50 Stock Review – Electronic Related: CLS, COHR, LITE, TTMI, SANM, FN, JBL, VICR
7) 24:15 Stock Review – Energy/Data Center related: VRT, GEV, ORA, ROK, ATI, WLDN, NVT, AAOI, CIEN, DY
8) 27:40 Stock Review – Biotech/Medical: XBI (ETF), IBB (ETF), AZN, RYTM, AVTX, NAMS, IMVT, CSTL, ORKA, SION, MAZE, INBX, MDGL, UTHR, GRAL, GH, NTRA, WGS
9) 31:55 Stock Review – Others/General Ideas/Commentary: TWLO, APP, NEM, HOOD, SOFI, GOOGL, SPHR, REMX (ETF)
10) 33:55 Stocks Near Buyable Ranges: AZN, IMVT
11) 35:50 Conclusion/Summary

Market Summary:
One theme I consistently talk about is using a Friday decisive close below the 10-week as a suggested stop. The reason I suggest waiting until Friday is that often times, the market and individual stocks will have shakeouts below this key level early in the week, and then recover to close above it by the end of the week. I bring this up because it happened this past week with the Nasdaq Composite, the S&P 500, and many growth stocks (some of which I highlight in this video). Why does this happen? Because the market is not designed to be easy. It constantly wants stop people out and create doubt through shakeouts, pullbacks and corrections. One way to combat this is to use lighter positions and expand your timeframe. Also, getting strong entry points can give you a cushion to help deal with this volatility.

How did I handle the shakeout this past week? As I mentioned in the MidWeek Video, I reduced my exposure from approximately 90% invested down to 60% by Wednesday, and when the price action improved later in the week, I finished the week approximately 80% invested. In this video, I explain this in more detail. From here, I’m going to do my best to shut out the noise and manage my positions as best as possible. Overall, I think this uptrend will continue until approximately mid-February but it won’t be straight up. We will continue to have shakeouts along the way, just like the one we had this week. That’s why it is very important to know your timeframe and stick to a plan that works with your overall investment plan. Thank you and enjoy the remainder of your weekend.

Unusual Options Activity:
12/19/25 S&P 500 ETF (SPY) 2400 Jan 23rd $685 calls bought $8.75 to $9
12/19/25 Dow Jones ETF (DIA) 3000 Jan 30th (W) $490 calls bought 4.49 to 4.80
12/19/25 Tech ETF (XLK) 6000 June 2027 $145 calls being sold to open
12/19/25 Silver ETF (SLV) 16,000 Jan 2027 $75/$95 call spreads bought 2.88
12/19/25 Silver ETF (SLV) also opening sellers of 20,000 Jan 2nd $58 puts at $0.90
12/19/25 Tesla (TSLA) opening sales of 2500 Sept $480 puts at $82.15 to $82
12/19/25 Rivian (RIVN) buyers in Jan $24 calls 5000X
12/19/25 Rivian (RIVN) 6000 Feb $25 calls bought
12/19/25 Lowe’s (LOW) 500 February $230 short puts open 4.15
12/19/25 Expand Energy (EXE) 12,560 March $95 short puts open 2.47 adjusting Jan. 105
12/19/25 Bloom Energy (BE) buyer 300 April $80 calls $28.30
12/19/25 Bloom Energy (BE) huge surge and 4500 Feb $90 puts sell to open $16 to $15.70
12/19/25 ConocoPhillips (COP) opening sales of 725 May $95 puts at $7.45
12/19/25 KKR (KKR) opening sales of 1600 Feb $115 puts at $2.12
12/19/25 SoFi (SOFI) stock replacements buying 8800 Feb $31 calls at $1.34 offers
12/19/25 SoFi (SOFI) 1100 Jan 2028 $20 short puts open for 4.75
12/19/25 Citigroup (C) seeing 8900 Feb $120/$130 call spreads bought at $2.30
12/19/25 Eli Lilly (LLY) 1025 Feb $890 short puts open for 11.15
12/19/25 Abivax (ABVX) buyers 2000 Jan $110 calls over $4M
12/19/25 United Health (UNH) opening sale 600 July 2026 $300 puts for 19.50
12/19/25 Ondas Holdings (ONDS) buyers of 4500 March $13 calls
12/19/25 Intuitive Machines (LUNR) 1100 June $14 calls buying $4.65 to $4.85
12/19/25 Intuitive Machines (LUNR) also June $12 calls buying 2000x at $5.50
12/19/25 Rocket Lab (RKLB) buyer of 3500 Feb $60 calls at $15.91 as the Jan $40 calls adjust
12/19/25 Micron (MU) buyer 1250 February $320 calls for 9.30
12/19/25 Micron (MU) 1000 Jan $270 ITM puts sell to open $18.10
12/19/25 Micron (MU) opening sales of 3000 Feb $250 puts at $18.50 to $18.50
12/19/25 Advanced Micro (AMD) 3000 Jan 9th $220/$230 call spreads bought
12/19/25 Google (GOOGL) buyers 3000 June $320 calls for $7.5M
12/19/25 Dell (DELL) large opening sale 1000 Dec 2026 $105 puts for 12.45
12/19/25 Broadcom (AVGO) stock replacements sell 700 Dec 2026 $270 puts at $28.15
12/19/25 ON Semi (ON) buyer 3000 Sept $85 calls for 2.27
12/19/25 Photronics (PLAB) buyer 2000 March $40 calls for 1.23
12/19/25 Nebius Group (NBIS) 1000 Feb $90 ITM puts sell to open at $14.50 bids
12/19/25 Meta (META) 2000 Feb $720 ITM puts sell for $71.25 to $70.50 as Jan short puts adjust
12/19/25 Apple (AAPL) 1000 Sept 2026 $230 puts sold 8.05 bid
12/19/25 Applied Materials (AMAT) opening sale 600 Feb $250 puts at 14.10
12/19/25 Arista Networks (ANET) buyer 600 June $140 calls 15.50
12/19/25 Veeva Systems (VEEV) buyer 350 Jan 2027 $230 calls 32.30 to 33.10
12/19/25 Amazon (AMZN) more of the Feb $225 calls buying at $15 with 6000x trading today
12/19/25 SanDisk (SNDK) buyers of 650 March $240 calls at $44.50 to $47.68
12/19/25 Dell (DELL) stock replacement sold to open 600 July $125 puts at $16.65
12/19/25 Marvell Tech (MRVL) 400 August $80 puts sell to open $11.15
12/19/25 Microsoft (MSFT) large buyer of 2500 Jan 2028 $300 deep ITM calls for $214.30 as Jan 2027 $290 calls adjust
12/19/25 Vistra (VST) over 4000 Jan 23rd (W) $135 short puts open for 1.17
12/19/25 Centrus Energy (LEU) 1000 Jan $270 ITM puts sell to open $32 to $28
12/18/25 S&P 500 ETF (SPY) 1000 March 2027 $770/$640 bull risk reversals opening at a net credit around $15
12/18/25 Nasdaq 100 ETF (QQQ) buyer 1000 March 31st (Q) $610 calls for 28.40
12/18/25 Nasdaq 100 ETF (QQQ) buyer of 1000 April $605 calls at $34.67
12/18/25 Nasdaq 100 ETF (QQQ) opening sale 1000 Dec 2027 $465 puts for 22.50
12/18/25 Russell 2000 ETF (IWM) stock replacement bought 1500 Dec 2026 $255 calls 21.90
12/18/25 Silver ETF (SLV) buyer of 5000 Jan 2027 $65 calls at $8.19 as March $60 calls adjust
12/18/25 Housing ETF (ITB) buyers in Feb $105 calls today 6000X
12/18/25 Tesla (TSLA) Feb $650 way OTM calls buying 7.55 and higher 6000X
12/18/25 Tesla (TSLA) buyer 37,200 Feb $650 calls 8.65 adjusting next week $510 calls
12/18/25 Tesla (TSLA) buyers in Feb $645, $655 and $660 calls, looks like call sweep ladders, all over 3000+ and in addition to the big $650 calls bought
12/18/25 Rivian (RIVN) buyer 12,500 June $25 calls $2.34
12/18/25 Wingstop (WING) 500 Jan 2027 $165 puts sell to open $17.80
12/18/25 Uber (UBER) buyer 750 Jan 2028 $80 calls $20.80
12/18/25 Starbucks (SBUX) opening seller of 1600 March $90 puts at $6.16
12/18/25 Exxon (XOM) large buyers of 9000 Sept $110 ITM calls at $12.90 to $13.12 as June calls adjusting
12/18/25 Wells Fargo (WFC) 1850 April 82.50 short puts open 2.10
12/18/25 Citigroup (C) 1350 June 2027 $155 call buyers $4.80 offer sweeps
12/18/25 Nasdaq (NDAQ) 1450 Jan 92.50 calls buy 3.50 to 3.60
12/18/25 Abivax ADR (ABVX) buyer 500 Feb $120 calls for $1M
12/18/25 Boston Scientific (BSX) opening sale of 750 June $95 puts at $5.80
12/18/25 Vertiv (VRT) 1600 Jan 2nd (W) $150 short puts open $3.60
12/18/25 Modine Manufacturing (MOD) buyer 500 Jan $140 calls at $8
12/18/25 GE Vernova (GEV) 1050 Jan $540 short puts open 5.40
12/18/25 Honeywell (HON) June $230 calls bought 1040X 4.10 to 4.20
12/18/25 Honeywell (HON) buyer 900 June $220 calls at $5.90 to $6.50
12/18/25 Rockwell Automation (ROK) opening seller 2045 Feb $360 puts $5.90
12/18/25 nVent Electric (NVT) 1300 Feb $105 calls bought against $125 calls
12/18/25 Quanta Services (PWR) 1300 Jan $450/$360 bull risk reversals opening as Dec adjust
12/18/25 Broadcom (AVGO) buyer 1000 Jan 9th (W) $335 calls 11.70
12/18/25 Broadcom (AVGO) buyer 500 June 2027 $600 calls 22.70
12/18/25 Broadcom (AVGO) large opening sale of 1000 Jan 30th $350 ITM puts for $33.50
12/18/25 Celestica (CLS) 1350 June $320/$370 call spreads bought
12/18/25 Celestica (CLS) 4150 Jan 30th (W) $165 short puts opening 1.60
12/18/25 Amazon (AMZN) buyer 21,000 Feb $210 calls $23.25 adjusting the $220 strike
12/18/25 Palantir (PLTR) 30,000 March $160 calls buy for $118M adjusting Feb 160 calls
12/18/25 Microsoft (MSFT) large buy 1300 June 2028 $490 calls at $102
12/18/25 Meta (META) massive opening sale of 6000 Jan 23rd $670 ITM puts at $21.35 to $21, over $13M in premium
12/18/25 Google (GOOGL) Feb $290 puts with 5000X sold
12/18/25 Arm Holdings ADR (ARM) opening sales of 675 Jan 2027 $105 puts at $17
12/18/25 SanDisk (SNDK) buyers of 1000 Jan 2nd $260 calls at $3.90
12/18/25 Oklo (OKLO) 1750 Jan 2027 $42 short puts open 8.45

Immunovant (IMVT) late strength off lows on 12/18 as unusual 1000 July $30 calls bought $4.48 to $4.60. The action follows a 12/11 purchase of 1500 May $30 calls and 625 January $26 calls. IMVT short interest at 8.6% of the float is down from 13% in May. IMVT shares have seen strong accumulation since October and making multi-month highs. IMVT was highlighted as a M&A target in a 10/30 Betaville report.

Immunovant is developing fully human monoclonal antibodies that block the neonatal Fc receptor (FcRn), which normally recycles IgG antibodies; inhibiting FcRn accelerates IgG clearance and reduces pathogenic autoantibodies in a wide range of autoimmune diseases. Batoclimab is the first‑generation FcRn antibody; it achieves deep IgG lowering but can affect LDL cholesterol and albumin at higher doses. IMVT‑1402 is a next‑generation FcRn inhibitor designed to match batoclimab’s deep IgG reductions while having minimal impact on LDL and albumin, which could support broader and more chronic use. Batoclimab has delivered positive results in several immune‑mediated diseases. These results underpin the core thesis that very deep IgG lowering (≥70%) can drive robust and durable responses in autoantibody diseases, which Immunovant expects IMVT‑1402 to match or exceed with a cleaner safety profile. The broader FcRn market is expected to grow from about US$2.36 billion in 2025 to US$3.37 billion by 2035, spanning neurology, rheumatology, endocrinology, dermatology, hematology, renal, and other areas; differentiation on depth and durability of IgG lowering, safety, and convenience will be critical.​

IMVT has a $5.27B market cap and trades 10.1X Cash as a clinical-stage biotech. Management has stated this cash provides runway through key Graves’ disease readouts expected in 2027 for the currently announced indications. In December 2025, Immunovant announced a $550 million stock offering at $21 per share, backed by majority owner Roivant Sciences. Citi has a $57 target seeing blockbuster potential for IMVT-1402.